Organization · Venture Capital
Sofinnova Investments
Sofinnova Investments is a Menlo Park-based healthcare investment firm specializing in early-stage investments in life sciences companies, particularly in therapeutic drugs. Founded in 1976, it manages approximately $3.3 billion in assets.
Overview
What Sofinnova Investments does
What Sofinnova Investments is
Sofinnova Investments is a Menlo Park-based healthcare investment firm specializing in early-stage investments in life sciences companies, particularly in therapeutic drugs. Founded in 1976, it manages approximately $3.3 billion in assets.
How it participates in the startup ecosystem
The current public profile supports funder and event host capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1976
- Approximate age
- About 50 years
- Structured capabilities
- Funder · Event host
- Last reviewed
- April 26, 2026
Official channels
Find Sofinnova Investments elsewhere
Open the official website or a supported primary organization account.
Capability profile
Sofinnova Investments as a funder
Investment thesis
Sofinnova Investments backs life-science entrepreneurs who can change medicine through therapeutic innovation, partnering from drug development to IPO.
Focus narrative
Sofinnova Investments invests in late preclinical and clinical therapeutic companies across the United States and Europe. The firm targets key therapeutic areas including oncology, respiratory, dermatology, ophthalmology, neurology, and women's health, aiming to support entrepreneurs in their journey to bring innovative therapies to market.
Value beyond capital
Sofinnova Investments adds value to its portfolio companies by providing not only financial capital but also strategic guidance in drug development, regulatory navigation, and preparation for IPOs. The firm emphasizes a hands-on approach to support entrepreneurs in achieving their milestones.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C · Series D · Series E · Growth Equity · Ipo
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 118
- Recorded notable exits
- Visen, Marea, and Vera
Portfolio context
Sofinnova has funded 118 companies, resulting in 55 IPOs and 30 mergers and acquisitions. Notable portfolio companies include: Visen: Approved treatment for pediatric growth hormone deficiency. Marea: Positive Phase 1 data for a treatment in acromegaly. Vera: Received priority review from the FDA for a treatment for IgA nephropathy. Expedition Therapeutics: Developing therapies for serious inflammatory and respiratory diseases. ARTBIO: Focused on targeted alpha radioligand therapies for solid tumors.
Capability profile
Sofinnova Investments as an event host
Event focus
Sofinnova Investments specializes in investing in late preclinical and clinical therapeutic companies across the United States and Europe. The firm emphasizes key therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology, and women's health, partnering with entrepreneurs to innovate and improve healthcare.
Participant value
Sofinnova Investments provides substantial support to life-science entrepreneurs, offering both human and financial capital to navigate drug development and regulatory processes, ultimately aiming for successful IPOs and mergers.
Format and cadence
- Startups can present
- No
Availability
- Registration state
- Not currently accepting
- Next recorded event
- January 12, 2026
- Next event location
- San Francisco, CA
Audience and fit
- Audience
- Founders · Investors
- Regions
- North AmericaEurope
Speakers and past editions
Speakers
Key team members include Jim Healy, MD, PhD - Managing Partner; Maha Katabi, PhD, CFA - General Partner; David Kabakoff, PhD - Executive Partner, Private Equity; Lars Ekman, MD, PhD - Executive Partner, Private Equity; Perry Nisen, MD, PhD - Executive Advisor, Private Equity; Jonathan Leff, MD - Executive Partner, Private Equity; Chris Carpenter, MD, PhD - Executive Partner, Private Equity; Jakob Dupont, MD - Executive Partner, Private Equity; Maha Radhakrishnan, MD - Executive Partner, Private Equity; Troy Ignelzi - Executive Advisor, Private Equity; Mike Van, PhD - Associate, Private Equity; Naomi Pacalin, PhD - Associate, Private Equity; Eric Hsu, PhD - Analyst, Private Equity; Nathalie Auber - Partner & CFO; Eric Delbridge, MD - General Partner, Public Equity; Aneal Tenjarla - Partner, Associate Portfolio Manager, Public Equity; Raymond Bower, MD - Portfolio Manager, Synergy Fund.
Common questions
What to know about Sofinnova Investments
Upseed classifies Sofinnova Investments under the Venture Capital organization type. Its current public profile includes funder and event host capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.